We dream big by thinking small, at the cellular level, inventing ways to destroy cancer and advance humanity.

CART-ddBCMA is now anitocabtagene autoleucel

View Arcellx’s presentation from the 2023 ASH Annual Meeting that was held in San Diego, CA, December 9-12, 2023.

Dr. Matthew Frigault shared updated clinical data from our Phase 1 clinical trial of anitocabtagene autoleucel (CART-ddBCMA) for the treatment of patients with RRMM. (Abstract 1023)

Click below to view the presentation announcing updated clinical data from our Phase 1 trial in RRMM.

Reimagining cell therapy

Powered by our novel D-Domain technology and paired with our transformative ddCAR and ARC-SparX platforms, our unique approach to cell therapy aims to supercharge how the world treats cancer.

Our Technology

with every cell of our being

From the very beginning, our team has been united to destroy cancer and challenge convention—while ensuring patients stay at the forefront.

Mission-critical collaboration

Every day, we are building a more purposeful, empathetic team ready to work together to spearhead change and transform the fight against cancer. Join us.

OUR CULTURE & CAREERS

Latest News